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Psoriatic arthritis
Nail involvement is part of the clinical spec-
trum of psoriatic disease and is microanatom-
ically associated with distal interphalangeal 
joint (DIPJ) entheses.1 Tumour necrosis 
factor (TNF) inhibitors have shown efficacy 
for psoriasis, arthritis, enthesitis, dactylitis and 
nail disease.2 Given the intimate links between 
psoriatic arthritis (PsA) and nail disease, it 
might be expected that nail disease improve-
ment would be associated with resolution of 
the underlying arthropathic features.
All participants gave written consent. All cases 
fulfilled the Classification Criteria for Psoriatic 
Arthritis (CASPAR) criteria for PsA.3 All cases 
were due to start TNF inhibitor therapy for 
active PsA. A clinical and MRI assessment was 
performed at baseline and after 6 months of 
treatment.
High-resolution MRI was performed on one 
finger, with gadolinium contrast and Vase-
line applied to the nail.4 The target finger for 
imaging was selected for current nail disease 
and active DIPJ arthritis. The MRIs were scored 
as previously reported.5 Seven patients were 
recruited. All patients had tenderness and 
swelling of the target finger’s DIPJ at baseline. 
TNF inhibitor prescription was made according 
to the National Institute for Health and Care 
Excellence guidelines. Four patients received 
etanercept and three adalimumab.
Marked improvements were seen in clin-
ical parameters at 6 months. No patients 
had residual clinical swelling in the target 
DIPJ and one had persistent tenderness 
(table 1). Onycholysis and pitting were the 
most frequent abnormalities at baseline. Two 
patients had completely normal nails in the 
target finger at 6 months, with no difference 
in nail clearance between nail matrix features 
and nail-bed abnormalities.
Baseline MRI scans showed DIPJ enthesitis, 
bone marrow oedema (BMO) or synovitis in 
all patients (86%, 71% and 100%, respec-
tively) (table 2). Collateral ligament enthe-
sopathy was seen in 86%, flexor tendon 
enthesopathy in 71% and extensor tendon 
enthesopathy in 86%. Three patients with 
purely nail-bed nail disease at baseline also 
had marked underlying BMO, synovitis and 
enthesitis on MRI.
Follow-up MRI scans surprisingly showed 
persistent inflammatory changes in the DIPJ, 
distal phalanx and soft tissues around the nail 
(table 2, figure 1). No patient with baseline 
BMO showed complete resolution, and four of 
the five had no change in BMO score. All seven 
patients had synovitis at baseline; this resolved 
in two, improved in one, was unchanged in 
three and worsened in one patient. No patient 
Key messages
What is already known about this subject?
 ► Nail involvement is part of the clinical spectrum of 
psoriatic arthritis and responds to tumour necrosis 
factor (tNF) inhibitors.
What does this study add?
 ► this small study assessed patients with psoriatic 
arthritis with nail disease and active distal 
interphalangeal (DIp) arthritis before and after 
6 months of tNF inhibitor treatment.
 ► persistent inflammatory changes in and around the 
DIp joint were seen on follow-up MrI scans despite 
a good clinical response.
How might this impact on clinical practice?
 ► Further studies are needed to see whether these 
inflammatory changes resolve with a longer 
duration of treatment or relate to radiographic 
progression of the arthritis.
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had complete resolution of extensor tendon abnormalities. 
Collateral ligament abnormalities were largely unchanged. 
No relationship was seen between the MRI changes and 
clinical response to treatment.
Previous PsA MRI studies have shown conflicting data 
regarding the resolution of inflammation with TNF 
inhibitors, some reporting improvements or resolution, 
others finding persistent inflammation.6–10 In one 
study, greater reductions in BMO volume were seen 
at 18 months than 6 months.10 Our data are limited 
by the small number of patients and short duration 
of follow-up. In conclusion, our study demonstrated 
persistent subclinical musculoskeletal inflammation on 
MRI despite a good clinical response. Further imaging 
in larger cohorts with a longer duration of follow-up is 
needed to demonstrate the natural history of inflam-
matory lesions under therapy and the potential link to 
disease progression.
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Table 1 Clinical assessments
Baseline 6 months
PASI
Median (range)
2.9 (0.2–7.3) 0.2 (0–1.8)
Swollen joint count
Mean (SD)
11 (6) 1 (1)
Tender joint count
Mean (SD)
12 (7) 1 (1)
SPARCC Enthesitis Index
Mean (SD)
3.4 (2) 0.4 (1)
mNAPSI
Mean (SD)
28 (15) 9 (6)
mNAPSI in the target finger
Median (range)
3 (3–5) 1 (0–2)
Visual analogue score for nail 
pain
Median (range)
12 (0–60) 0 (0–2)
PASI, Psoriasis Area and Severity Index; SPARCC, 
Spondyloarthritis Research Consortium of Canada Enthesitis 
Index; mNAPSI, modified Nail Psoriasis Severity Index. 
Table 2 MRI scores for each patient
Patient
BMO score (0–3)
Synovitis score 
(0–2)
CommentsBaseline
Follow-
up Baseline
Follow-
up
A 0 0 1 0 No enthesitis
B 2 2 2 2 Marked changes 
but overall 
improvement
C 3 3 1 2 Effusion 
resolved at 
follow-up
D 2 1 2 0 Flexor tendon 
changes 
resolved
E 0 0 1 1 Persistent 
enthesopathy 
collateral 
ligaments and 
extensor tendon
F 2 2 2 2 Overall 
improvement 
on follow-up 
scan despite 
persistent BMO
G 1 1 2 1 Marked 
improvement 
in collateral 
ligaments
BMO, bone marrow oedema.
Figure 1 Nail photographs and MRI scans of a patient with 
psoriatic arthritis. Improvements in the nail appearances are 
seen on the photograph. Vaseline (asterisk) is seen overlying 
the nail on MRI. At baseline, a large enthesophyte is seen at 
the extensor tendon enthesis (white arrow) with diffuse bone 
marrow changes (black arrow). After 6 months of treatment 
with etanercept, persistent bone marrow changes are seen 
(black arrow), with a greater degree of synovitis.
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